@article{aba7a4138eef4cdfb1ba6d8503205175,
title = "An Empirical Examination of Symptom Substitution Associated With Behavior Therapy for Tourette's Disorder",
abstract = "Over the past six decades, behavior therapy has been a major contributor to the development of evidence-based psychotherapy treatments. However, a long-standing concern with behavior therapy among many nonbehavioral clinicians has been the potential risk for symptom substitution. Few studies have been conducted to evaluate symptom substitution in response to behavioral treatments, largely due to measurement and definitional challenges associated with treated psychiatric symptoms. Given the overt motor and vocal tics associated with Tourette's disorder, it presents an excellent opportunity to empirically evaluate the potential risk for symptom substitution associated with behavior therapy. The present study examined the possible presence of symptom substitution using four methods: (a) the onset of new tic symptoms, (b) the occurrence of adverse events, (c) change in tic medications, and (d) worsening of co-occurring psychiatric symptoms. Two hundred twenty-eight participants with Tourette's disorder or persistent motor or vocal tic disorders were randomly assigned to receive behavioral therapy or supportive therapy for tics. Both therapies consisted of eight sessions over 10 weeks. Results indicated that participants treated with behavior therapy were not more likely to have an onset of new tic symptoms, experience adverse events, increase tic medications, or have an exacerbation in co-occurring psychiatric symptoms relative to participants treated with supportive therapy. Further analysis suggested that the emergence of new tics was attributed with the normal waxing and waning nature of Tourette's disorder. Findings provide empirical support to counter the long-standing concern of symptom substitution in response to behavior therapy for individuals with Tourette's disorder.",
keywords = "Behavior therapy, Chronic tic disorder, Comprehensive behavioral intervention for tics, Symptom substitution, Tourette's disorder",
author = "Peterson, {Alan L.} and McGuire, {Joseph F.} and Sabine Wilhelm and John Piacentini and Woods, {Douglas W.} and Walkup, {John T.} and Hatch, {John P} and Robert Villarreal and Lawrence Scahill",
note = "Funding Information: This research was supported by National Institute of Mental Health (NIMH) Grants R01MH070802 (Dr. Piacentini), R01MH069874 (Dr. Scahill), RO1MH069875 (Dr. Peterson), and 5R01MH069877 (Dr. Wilhelm) from the NIMH with subcontracts to Drs. Walkup and Woods. The funding agency played no role in the study design; collection, analysis, or interpretation of data; the writing of this article; or the decision to submit the article for publication. Funding Information: Drs. Peterson, Wilhelm, Piacentini, Woods, Walkup, and Scahill report receiving royalties from Oxford University Press for treatment manuals on tic disorders. Drs. Peterson, Wilhelm, Piacentini, Woods, Walkup, and Scahill report receiving honoraria for continuing education presentations from the Tourette Syndrome Association. Drs. Piacentini, Woods, and Walkup receive royalties from Guilford Press for a book on Tourette's disorder. Dr. Wilhelm reports receiving support in the form of free medication and matching placebo from Forest Laboratories for clinical trials funded by the National Institutes of Health (NIH) and receiving royalties from Guilford Publications, Springer, John Wiley, New Harbinger Publications, and Oxford University Press. She received research funding from the International Obsessive Compulsive Disorder Foundation, Novartis, and the Tourette{\textquoteright}s Syndrome Association, as well as consulting funds from the Mayo Foundation for Medical Education and Research. Dr. Piacentini also reports receiving support for his work from NIMH, Pfizer, and the Pettit Family Foundation and speaking honoraria from the International OCD Foundation. Dr. Woods reports receiving book royalties from New Harbinger and Springer Publications. Dr. Scahill has received royalties from Oxford University Press and American Psychiatric Press; has served as a consultant for Boehringer-Ingelheim, NeuroSearch, and Pfizer; and has had research support from Shire Pharmaceutical and Seaside Therapeutics. He also reports receiving support in the form of free medication and matching placebo from Shire Pharmaceuticals for a clinical trial funded by NIMH. Dr. Walkup reports receiving consulting fees from Eli Lilly and JAZZ Pharmaceuticals and lecture fees from CMP Media, Medical Education Reviews, McMahon Group, DiMedix, and the Tourette Disorder Association. He reports receiving free drug and matching placebo from Pfizer and Lilly and free drugs from Abbott for NIMH-funded clinical trials. He reports receiving fees for consultation with defense counsel and submission of written reports in litigation involving GlaxoSmithKline. Publisher Copyright: {\textcopyright} 2015.",
year = "2016",
month = jan,
day = "1",
doi = "10.1016/j.beth.2015.09.001",
language = "English (US)",
volume = "47",
pages = "29--41",
journal = "Behavior Therapy",
issn = "0005-7894",
publisher = "Elsevier Inc.",
number = "1",
}